2025 is proving to be a decisive year for the adoption of Artificial Intelligence in the healthcare sector. According to data published by Crunchbase, European startups active in AI and healthcare have already raised more than 10.7 billion dollars, a 24.4% increase compared to the entire year 2024.
This acceleration signals a transformation already underway: healthcare is becoming increasingly digital, predictive, and data-driven. But as investments grow, so does the demand for concrete evidence. The era of promises is over. What’s needed now is proof of clinical effectiveness, operational impact, and economic sustainability.
What investors, clinicians, and decision-makers are looking for
The maturation of the sector brings a paradigm shift: AI solutions are no longer evaluated solely for their technological innovation, but for their ability to integrate into real healthcare workflows, reducing time and costs while improving the quality and accessibility of services.
Professionals working in this field must be able to document tangible results: model sensitivity and specificity, reduction of clinicians’ workload, and improved diagnostic and therapeutic efficiency.
An opportunity for consolidation and growth
For Health Triage, a company active for years in developing AI solutions for oncological diagnostic support, the current context represents an extraordinary opportunity for consolidation and growth. Research activities focus on developing deep learning models along two main lines:
- BreastNegative, a medical device that automatically identifies negative mammograms in screening programs.
- Prostate V-Bio, a non-invasive AI system based on MRI that classifies prostate cancer into categories corresponding to pathological Gleason Grades.
Both projects have already passed rigorous technical validation and will undergo further clinical verification phases, with the goal of offering clinically reliable solutions that are fully integrated and scalable at national and international levels.
Three strategic priorities to accelerate progress
Given market developments and sector expectations, operational priorities are clear:
-
Clinical validation and scientific transparency
Publishing certified results is the first step toward building credibility. Every AI model must be tested, documented, and compared against current standards in a transparent and reproducible manner. -
Impact-oriented communication
It’s not enough to explain what the technology does; it’s essential to show what it actually changes. How many hours are saved? How much earlier can a diagnosis be made? What measurable benefits exist for patients and healthcare professionals? -
Regulatory compliance and ethical data management
Data governance, privacy protection, and compliance with European regulations are not obstacles but essential conditions for operating in this field. Those who demonstrate safety, transparency, and traceability gain a competitive advantage.
Conclusions
Artificial Intelligence is entering clinical practice in a concrete way. Health Triage is contributing to this evolution with solutions such as BreastNegative and Prostate V-Bio, designed to improve diagnostic efficiency and support oncological prevention programs.
The work continues, with constant attention to quality, integration, and scientific validation. For AI to fully express its potential, regulatory progress is also needed. Clear guidelines, shared protocols, and structured pathways must be established to ensure its safe and effective adoption in clinical practice.
It is time to start using AI—with rigor and responsibility.
